Reference Material

1. Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: A review. Bull World Health Organ. 2007;85:719–726.

2. Bonde JH, Sandri M, Gary DS, Andrews JC. Clinical utility of human papillomavirus genotyping in cervical cancer screening: A systematic review. Journal of Lower Genital Tract Disease. 2020;24(1). https://journals.lww.com/jlgtd/fulltext/2020/01000/clinical_utility_of_human_papillomavirus.1.aspx.

3. Walls S. Human papillomavirus (HPV) strains 6 and 11 and strains 16 and 18. Embryo Project Encyclopedia ( 2021-04-06 ) Web site. https://hdl.handle.net/10776/13250. Updated 2021.

4. Rodrigues R, Sousa C, Vale N. Chlamydia trachomatis as a current health problem: Challenges and opportunities. Diagnostics. 2022;12(8). doi: 10.3390/diagnostics12081795.

5. Lesiak-Markowicz I, Schötta A, Stockinger H, Stanek G, Markowicz M. Chlamydia trachomatis serovars in urogenital and ocular samples collected 2014–2017 from austrian patients. Scientific reports. 2019;9(1):18327.

6. Morré SA, Rozendaal L, Van Valkengoed I, et al. Urogenital chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: An association with clinical manifestations? J Clin Microbiol. 2000;38(6):2292–2296.

7. Witkin SS, Minis E, Athanasiou A, Leizer J, Linhares IM. Chlamydia trachomatis: The persistent pathogen. Clinical and Vaccine Immunology. 2017;24(10):203.

8. Bellaminutti S, Seraceni S, De Seta F, Gheit T, Tommasino M, Comar M. HPV and chlamydia trachomatis co‐detection in young asymptomatic women from high incidence area for cervical cancer. J Med Virol. 2014;86(11):1920–1925.

9. Seo Y, Choi K, Lee G. Characterization and trend of co-infection with neisseria gonorrhoeae and chlamydia trachomatis from the korean national infectious diseases surveillance database. The world journal of men’s health. 2019;39(1):107.

10. de Miranda Lima L, Hoelzle CR, Simões RT, et al. Sexually transmitted infections detected by multiplex real time PCR in asymptomatic women and association with cervical intraepithelial neoplasia. Revista Brasileira de Ginecologia e Obstetrícia/RBGO Gynecology and Obstetrics. 2018;40(09):540–546.

11. Landhuis EW. Multidrug-resistant “super gonorrhea” rallies multipronged effort. JAMA. 2024;331(20):1695–1697. https://doi.org/10.1001/jama.2023.15355. doi: 10.1001/jama.2023.15355.

12. Greydanus D, Bacopoulou F. Acute pelvic inflammatory disease. Pediatric Medicine. 2019;2:36. doi: 10.21037/pm.2019.07.05.

13. Peris MP, Alonso H, Escolar C, et al. Detection of chlamydia trachomatis and neisseria gonorrhoeae (and its resistance to ciprofloxacin): Validation of a molecular biology tool for rapid diagnosis and treatment. Antibiotics. 2024;13(11). doi: 10.3390/antibiotics13111011.

14. Horner PJ, Martin DH. Mycoplasma genitalium infection in men. J Infect Dis. 2017;216:S396–S405. https://doi.org/10.1093/infdis/jix145. doi: 10.1093/infdis/jix145.

15. Jensen JS, Cusini M, Gomberg M, Moi H, Wilson J, Unemo M. 2021 european guideline on the management of mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2022;36(5):641–650. https://doi.org/10.1111/jdv.17972. doi: 10.1111/jdv.17972.

16. Horner PJ, Blee K, Falk L, van der Meijden W, Moi H. 2016 european guideline on the management of non-gonococcal urethritis. Int J STD AIDS. 2016;27(11):928–937.

17. Margareth Larose-Pierre &, Chenita Carter &, Marlon S. Honeywell. Aptima mycoplasma genitalium assay. U.S. Pharm. 2019;44(4):31–34.

18. Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: Global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548.

19. Kissinger PJ, Gaydos CA, Seña A,C., et al. Diagnosis and management of trichomonas vaginalis: Summary of evidence reviewed for the 2021 centers for disease control and prevention sexually transmitted infections treatment guidelines. Clin Infect Dis. 2022;74:S152–S161. https://doi.org/10.1093/cid/ciac030. doi: 10.1093/cid/ciac030.

20. Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of trichomonas vaginalis. Clin Microbiol Rev. 1998;11(2):300–317.

21. Martinez-Garcia F, Regadera J, Mayer R, Sanchez S, Nistal M. Protozoan infections in the male genital tract. J Urol. 1996;156(2):340–349.

22. Kissinger P, Adamski A. Trichomoniasis and HIV interactions: A review. Sex Transm Infect. 2013;89(6):426–433.

23. Wendel KA, Workowski KA. Trichomoniasis: Challenges to appropriate management. Clinical Infectious Diseases. 2007:S123–S129.

24. Waites KB, Schelonka RL, Xiao L, Grigsby PL, Novy MJ. Congenital and opportunistic infections: Ureaplasma species and mycoplasma hominis. Seminars in Fetal and Neonatal Medicine. 2009;14(4):190–199. https://www.sciencedirect.com/science/article/pii/S1744165X08001467. doi: 10.1016/j.siny.2008.11.009.

25. Ahmed J, Rawre J, Dhawan N, Khanna N, Dhawan B. Mycoplasma hominis: An under recognized pathogen. Indian Journal of Medical Microbiology. 2021;39(1):88–97. https://www.sciencedirect.com/science/article/pii/S0255085720300232. doi: 10.1016/j.ijmmb.2020.10.020.

26. Reissier S, Masson R, Guérin F, et al. Fatal nosocomial meningitis caused by mycoplasma hominis in an adult patient: Case report and review of the literature. International Journal of Infectious Diseases. 2016;48:81–83. https://www.sciencedirect.com/science/article/pii/S120197121631058X. doi: 10.1016/j.ijid.2016.05.015.

27. Song J, Wu X, Kong Y, et al. Prevalence and antibiotics resistance of ureaplasma species and mycoplasma hominis in hangzhou, china, from 2013 to 2019. Frontiers in Microbiology. 2022;olume 13 – 2022. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.982429.

28. Ahmadi MH. Resistance to tetracyclines among clinical isolates of mycoplasma hominis and ureaplasma species: A systematic review and meta-analysis. J Antimicrob Chemother. 2021;76(4):865–875. https://doi.org/10.1093/jac/dkaa538. doi: 10.1093/jac/dkaa538.

29. Waites K, Katz B, Schelonka R. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev. 2005;18:757–89. doi: 10.1128/CMR.18.4.757-789.2005.

30. Wang C, Wang J, Yan J, Chen F, Zhang Y, Hu X. Mycoplasma hominis, ureaplasma parvum, and ureaplasma urealyticum: Hidden pathogens in peritoneal dialysis-associated peritonitis. International Journal of Infectious Diseases. 2023;131:13–15. https://www.sciencedirect.com/science/article/pii/S120197122300108X. doi: 10.1016/j.ijid.2023.03.032.

31. Pollack JD. Ureaplasma urealyticum: An opportunity for combinatorial genomics. Trends Microbiol. 2001;9(4):169–175. https://doi.org/10.1016/S0966-842X(01)01950-3. doi: 10.1016/S0966-842X(01)01950-3.

32. Carneiro F, Darós A, Darós A, et al. Cervical cytology of samples with ureaplasma urealyticum , ureaplasma parvum , chlamydia trachomatis , trichomonas vaginalis , mycoplasma hominis , and neisseria gonorrhoeae detected by multiplex PCR. BioMed Research International. 2020;2020:1–10. doi: 10.1155/2020/7045217.

33. AlMukdad S, Harfouche M, Farooqui US, Aldos L, Abu-Raddad L. Epidemiology of herpes simplex virus type 1 and genital herpes in australia and new zealand: Systematic review, meta-analyses and meta-regressions. Epidemiol Infect. 2023;151:e33. https://www.cambridge.org/core/product/BD61C680ACCB4FBA808968879CC3999A. doi: 10.1017/S0950268823000183.

34. Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: Epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol. 2007;57(5):737–763.

35. Brady RC, Bernstein DI. Treatment of herpes simplex virus infections. Antiviral Res. 2004;61(2):73–81.

36. Alareeki A, Osman AMM, Khandakji MN, Looker KJ, Harfouche M, Abu-Raddad L. Epidemiology of herpes simplex virus type 2 in europe: Systematic review, meta-analyses, and meta-regressions. The Lancet Regional Health – Europe. 2023;25. https://doi.org/10.1016/j.lanepe.2022.100558. doi: 10.1016/j.lanepe.2022.100558.

37. Berger JR, Houff S. Neurological complications of herpes simplex virus type 2 infection. Arch Neurol. 2008;65(5):596–600. https://doi.org/10.1001/archneur.65.5.596. doi: 10.1001/archneur.65.5.596.

38. Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nature Reviews Immunology. 2022;22(1):19–32.

39. Locarnini S, Hatzakis A, Chen D, Lok A. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol. 2015;62(1):S76–S86.

40. Liang TJ. Hepatitis B: The virus and disease. Hepatology. 2009;49(S5):S13–S21.

41. Chen J, Li L, Yin Q, Shen T. A review of epidemiology and clinical relevance of hepatitis B virus genotypes and subgenotypes. Clinics and Research in Hepatology and Gastroenterology. 2023;47(7):102180. https://www.sciencedirect.com/science/article/pii/S2210740123001055. doi: 10.1016/j.clinre.2023.102180.

42. Gerlich WH. Medical virology of hepatitis B: How it began and where we are now. Virology Journal. 2013;10(1):239. https://doi.org/10.1186/1743-422X-10-239. doi: 10.1186/1743-422X-10-239.

43. Velkov S, Ott J, Protzer U, Michler T. The global hepatitis B virus genotype distribution approximated from available genotyping data. Genes. 2018;9:495. doi: 10.3390/genes9100495.

44. Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clinics and Research in Hepatology and Gastroenterology. 2021;45(3):101596. https://www.sciencedirect.com/science/article/pii/S2210740120303624. doi: 10.1016/j.clinre.2020.101596.

45. World Health Organization. Global hepatitis report 2017. Geneva: World Health Organization; 2017. https://iris.who.int/handle/10665/255016.

46. Piver E, Boyer A, Gaillard J, et al. Ultrastructural organisation of HCV from the bloodstream of infected patients revealed by electron microscopy after specific immunocapture. Gut. 2017;66(8):1487. http://gut.bmj.com/content/66/8/1487.abstract. doi: 10.1136/gutjnl-2016-311726.

47. Negro F, Lok AS. Hepatitis D: A review. JAMA. 2023;330(24):2376–2387. https://doi.org/10.1001/jama.2023.23242. doi: 10.1001/jama.2023.23242.

48. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut. 2000;46(3):420. http://gut.bmj.com/content/46/3/420.abstract. doi: 10.1136/gut.46.3.420.

49. Le Gal Frédéric, Samira D, Gerber Athenaïs, et al. Performance characteristics of a new consensus commercial kit for hepatitis D virus RNA viral load quantification. J Clin Microbiol. 2017;55(2):431–441. https://doi.org/10.1128/jcm.02027-16. doi: 10.1128/jcm.02027-16.

50. Kumar V, Das S, Jameel S. The biology and pathogenesis of hepatitis viruses. Curr Sci. 2010;98:312–325.

51. Garry RF. Lassa fever — the road ahead. Nature Reviews Microbiology. 2023;21(2):87–96. https://doi.org/10.1038/s41579-022-00789-8. doi: 10.1038/s41579-022-00789-8.

52. Doohan P, Jorgensen D, Naidoo TM, et al. Lassa fever outbreaks, mathematical models, and disease parameters: A systematic review and meta-analysis. The Lancet Global Health. 2024;12(12):e1962–e1972. https://doi.org/10.1016/S2214-109X(24)00379-6. doi: 10.1016/S2214-109X(24)00379-6.

53. Basinski AJ, Fichet-Calvet E, Sjodin AR, et al. Bridging the gap: Using reservoir ecology and human serosurveys to estimate lassa virus spillover in west africa. PLoS computational biology. 2021;17(3):e1008811.

54. Andersen KG, Shapiro BJ, Matranga CB, et al. Clinical sequencing uncovers origins and evolution of lassa virus. Cell. 2015;162(4):738–750. doi: 10.1016/j.cell.2015.07.020.

55. Carey BD, Yu S, Geiger J, et al. A lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs. npj Vaccines. 2024;9(1):220. https://doi.org/10.1038/s41541-024-01012-w. doi: 10.1038/s41541-024-01012-w.

56. Winter AK, Moss WJ. Rubella. The Lancet. 2022;399(10332):1336–1346.

57. Cardemil CV, Dahl RM, James L, et al. Effectiveness of a third dose of MMR vaccine for mumps outbreak control. N Engl J Med. 2017;377(10):947–956.

58. Damania B, Kenney SC, Raab-Traub N. Epstein-barr virus: Biology and clinical disease. Cell. 2022;185(20):3652–3670. https://doi.org/10.1016/j.cell.2022.08.026. doi: 10.1016/j.cell.2022.08.026.

59. Virus proteins prevent cell suicide long enough to establish latent infectionPLOS Biology. 2005;3(12):e430. https://doi.org/10.1371/journal.pbio.0030430.

60. Giraldo MI, Gonzalez-Orozco M, Rajsbaum R2. Pathogenesis of zika virus infection. Annual Review of Pathology: Mechanisms of Disease,. ;18(Volume 18, 2023):181–203. https://www.annualreviews.org/content/journals/10.1146/annurev-pathmechdis-031521-034739. doi: 10.1146/annurev-pathmechdis-031521-034739.

61. Reynolds MR. Vital signs: Update on zika virus–associated birth defects and evaluation of all US infants with congenital zika virus exposure—US zika pregnancy registry, 2016. MMWR.Morbidity and mortality weekly report. 2017;66.

62. Bernatchez JA, Tran LT, Li J, Luan Y, Siqueira-Neto J, Li R. Drugs for the treatment of zika virus infection. J Med Chem. 2020;63(2):470–489. https://doi.org/10.1021/acs.jmedchem.9b00775. doi: 10.1021/acs.jmedchem.9b00775.

63. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika virus. N Engl J Med. 2016;374(16):1552–1563. https://doi.org/10.1056/NEJMra1602113. doi: 10.1056/NEJMra1602113.

64. Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Frontiers in Immunology. 2023;olume 14 – 2023. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1125246.

65. Wang J, Han M, Roy AR, et al. Multi-color super-resolution imaging to study human coronavirus RNA during cellular infection. Cell Rep Methods. 2022;2(2):100170. doi: 10.1016/j.crmeth.2022.100170.

66. Hokello J, Sharma AL, Tyagi P, Bhushan A, Tyagi M. Human immunodeficiency virus type-1 (HIV-1) transcriptional regulation, latency and therapy in the central nervous system. Vaccines. 2021;9(11). doi: 10.3390/vaccines9111272.

67. Llibre JM, Brites C, Cheng C, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): Week 48 results from the phase 3, noninferiority SALSA randomized trial. Clin Infect Dis. 2023;76(4):720–729. https://doi.org/10.1093/cid/ciac130. doi: 10.1093/cid/ciac130.

68. Karacostas V, Nagashima K, Gonda M, Moss B. Human immunodeficiency virus-like particle produced by a vaccinia virus expression vector. Proc Natl Acad Sci U S A. 1989;86:8964–7. doi: 10.1073/pnas.86.22.8964.

69. Kaler J, Hussain A, Patel K, Hernandez T, Ray S. Respiratory syncytial virus: A comprehensive review of transmission, pathophysiology, and manifestation. Cureus. 2023;15(3).

70. Langedijk AC, Bont LJ. Respiratory syncytial virus infection and novel interventions. Nature Reviews Microbiology. 2023;21(11):734–749.

71. Ke Z, Dillard RS, Chirkova T, et al. The morphology and assembly of respiratory syncytial virus revealed by cryo-electron tomography. Viruses. 2018;10(8). doi: 10.3390/v10080446.

72. Javanian M, Barary M, Ghebrehewet S, Koppolu V, Vasigala V, Ebrahimpour S. A brief review of influenza virus infection. J Med Virol. 2021;93(8):4638–4646. https://doi.org/10.1002/jmv.26990. doi: 10.1002/jmv.26990.

73. Ljubin-Sternak S, Meštrović T. Rhinovirus—A true respiratory threat or a common inconvenience of childhood? Viruses. 2023;15(4). doi: 10.3390/v15040825.

74. Gern JE. The ABCs of rhinoviruses, wheezing, and asthma. J Virol. 2010;84(15):7418–7426.

75. Olson N, Kolatkar P, Oliveira M, et al. Structure of a human rhinovirus complexed with its receptor molecule. Proc Natl Acad Sci U S A. 1993;90:507–11. doi: 10.1073/pnas.90.2.507.

76. Costa-Filho R, Saddy F, Costa JL, Tavares LR, Castro Faria Neto HC. The silent threat of human metapneumovirus: Clinical challenges and diagnostic insights from a severe pneumonia case. Microorganisms. 2025;13(1). doi: 10.3390/microorganisms13010073.

77. Feuillet F, Lina B, Rosa-Calatrava M, Boivin G. Ten years of human metapneumovirus research. Journal of Clinical Virology. 2012;53(2):97–105. https://www.sciencedirect.com/science/article/pii/S1386653211004185. doi: 10.1016/j.jcv.2011.10.002.

78. Jumat MR, Nguyen Huong T, Wong P, et al. Imaging analysis of human metapneumovirus-infected cells provides evidence for the involvement of F-actin and the raft-lipid microdomains in virus morphogenesis. Virology Journal. 2014;11(1):198. https://doi.org/10.1186/s12985-014-0198-8. doi: 10.1186/s12985-014-0198-8.

79. Ott L, Möller J, Burkovski A. Interactions between the re-emerging pathogen Corynebacterium diphtheriae and host cells. International Journal of Molecular Sciences. 2022;23(6). doi: 10.3390/ijms23063298.

80. Shanmugam L, Priyadarshi K, Kumaresan M, et al. A rare case report of non-toxigenic corynebacterium diphtheriae bloodstream infection in an uncontrolled diabetic with peripheral vascular disease. Cureus. 2021;13(5).

81. Mattos-Guaraldi ALd, Formiga LCD. Bacteriological properties of a sucrose-fermenting corynebacterium diphtheriae strain isolated from a case of endocarditis. Curr Microbiol. 1998;37(3):156–158.

82. Patey O, Bimet F, Riegel PH, et al. Clinical and molecular study of corynebacterium diphtheriae systemic infections in france. coryne study group. J Clin Microbiol. 1997;35(2):441–445.

83. Govindaswamy A, Trikha V, Mathur P, Mittal S. An unusual case of post-trauma polymicrobial cutaneous diphtheria. 2019. doi: 10.1007/s15010-019-01300-x.

84. Montero DA, Vidal RM, Velasco J, et al. Vibrio cholerae, classification, pathogenesis, immune response, and trends in vaccine development. Frontiers in Medicine. 2023;olume 10 – 2023. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1155751.

85. Nadri J, Sauvageot D, Njanpop-Lafourcade B, et al. Sensitivity, specificity, and public-health utility of clinical case definitions based on the signs and symptoms of cholera in africa. Am J Trop Med Hyg. 2018;98(4):1021–1030. doi: 10.4269/ajtmh.16-0523.

86. Guha K, Vineetha KV, Sravani G, et al. Performance analysis of MEMS sensor for the detection of cholera and diarrehea. Microsystem Technologies, Springer. 2018;24. doi: 10.1007/s00542-018-3810-9.